TNFSF11 and Hypocalcemia: Denosumab, a humanized monoclonal antibody, specifically combines with RANKL and downregulates RANKL/RANK signaling (Lacey et al., 2012) and shares similar adverse effects with bisphosphonates, like osteonecrosis of the jaw, hypocalcemia, etc. (Iqbal et al., 2010; Chen and Smerdely, 2017; Otto et al., 2018).